Company intelligence / Profile preview
GRI Bio, Inc.
La Jolla, CA, USAgribio.com ↗
- Ownership
- Public · GRI
- Development stage
- Phase 1
01
Overview
The lead program, GRI‑0621—an oral iNKT cell inhibitor—is in a Phase 2a randomized double-blind study for idiopathic pulmonary fibrosis. Interim biomarker data are expected Q2 2025 and topline results Q3 2025. Additional programs include dNKT agonists for SLE in preclinical development. No efficacy or safety data have been publicly reported as of May 2025.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Small molecules (NKT cell modulators; oral therapeutics)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $3.4M
- Total revenue
- $0
- Enterprise value
- $-7.5M
Beyond the preview
Go deeper on GRI Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRI Bio, Inc..